RxDoctor Payments Data

Andrea Montgomery, NP

Psychiatric/Mental Health · Lafayette, LANPI 1548394737

Payments from drug & device makers

$563in general payments, 2019–2025

Across 36 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$185
  • Alkermes, Inc.$139
  • Sunovion Pharmaceuticals Inc.$131
  • AbbVie$34
  • Johnson & Johnson$27
  • Eisai Inc.$19
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$563 in reported general payments places this provider in the 30th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$20,716
Medicare patients
94
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$50,077
AristadaAripiprazole Lauroxil14$42,151
Aripiprazole73$1,866
Haloperidol Decanoate23$1,654
Oxcarbazepine41$1,465
Divalproex Sodium ErDivalproex Sodium45$1,222
Quetiapine Fumarate76$666
Duloxetine Hcl43$478
Risperidone39$416
Buspirone Hcl43$405
Trazodone Hcl93$404
Olanzapine36$335
Venlafaxine Hcl ErVenlafaxine Hcl27$305
Prazosin Hcl18$261
Benztropine Mesylate19$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$27$50,07720 claims
Alkermes, Inc.Aristada$139$42,15114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →